Pacific GeneTech Establishes Canadian Subsidiary and joins Emergence Bioincubator
HONG KONG, 1 March, 2021
Pacific GeneTech (PGT) has established a subsidiary, Pacific GeneTech Canada Ltd, in Prince Edward Island, Canada. A main focus of PGT Canada would be research in aquaculture applications for PGT’s technologies.
PGT has also joined a Canadian Biosciences Business Incubator, Emergence, which is dedicated to assisting growth-stage bioscience companies in efficiently bringing their products and services to market.
“Canada is an important center for vaccine research in both the animal and human fields, and Prince Edward Island is an internationally-recognized center for aquaculture research, particularly in salmonids. We are very pleased to be a part of the Emergence program which will enable us to tap into important new industry and scientific resources,” said Tim Collard, CEO, PGT.
ABOUT PACIFIC GENETECH
Pacific GeneTech (www.pacificgenetech.com) develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases. The PGT vaccines can be administered orally or by injection in both live and inactivated forms. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines, and its "Argo" yeast vector is a safe, flexible and robust carrier of immunogenic material.
PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development, including an experimental DNA vaccine for African Swine Fever. PGT is developing other applications for its Hercules adjuvant/delivery system and for the Argo vector. PGT, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery and related diseases, and malaria.
Tim Collard, CEO
Tel: +852 2525 8151